Is SciClone Pharma Getting Enough in the Buyout?

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 8 June, 2017 by The TZ Newswire Staff

Is SciClone Pharma Getting Enough in the Buyout?

SciClone Pharmaceuticals saw its shares make a solid gain early on Thursday after it was announced that the company entered into a definitive agreement to be acquired by a consortium of companies.

See also
- Next Article Draghi Q&A: Didn’t vote on decision but there were no dissenting voices
- Previous Article U.K. voters hit the polls, buzzed by uncertainty of the outcome
Editorial Calender

June 2017

M T W T F S S

1 2 3 4

5 6 7 8 9 10 11

12 13 14 15 16 17 18

19 20 21 22 23 24 25

26 27 28 29 30

« May Jul »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar

The Traderszone Network

Editorial Archives

Published in TZ Latest News 8 June, 2017 by The TZ Newswire Staff

Is SciClone Pharma Getting Enough in the Buyout?

See also

Editorial Calender

Recent Tags